Long-Term Effectiveness of Combined Alprazolam and Cognitive-Behavioral Therapies in Panic Disorder

Steven M. Bond, '95
Illinois Wesleyan University

Timothy J. Bruce, Faculty Advisor
University of Illinois College of Medicine, Peoria

Follow this and additional works at: https://digitalcommons.iwu.edu/jwprc

https://digitalcommons.iwu.edu/jwprc/1995/posters/39

This is protected by copyright and/or related rights. It has been brought to you by Digital Commons @ IWU with permission from the rights-holder(s). You are free to use this material in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/or on the work itself. This material has been accepted for inclusion by faculty at Illinois Wesleyan University. For more information, please contact digitalcommons@iwu.edu.

©Copyright is owned by the author of this document.
Benzodiazepines, particularly alprazolam, have been shown to be effective in the treatment of panic disorder. However, difficult withdrawal and high relapse rates after successful discontinuation continue to be problems with this class of medication. Recent studies instituting cognitive-behavioral therapy as a treatment supplement to alprazolam taper have shown promising results at short-term follow-up. The present study investigated whether these procedures produce long-term (two- to four-year) improvement. Patients were stabilized on alprazolam and randomly assigned to either an alprazolam-only group or the same condition with twelve weeks of concurrent cognitive-behavioral therapy. Twenty patients who completed these treatments were assessed at two- to four-year follow-up. In addition to the discontinuation success rates, self-report and clinician-rated measures concerning panic attack frequency, disability intensity, agoraphobic avoidance, and anxiety severity were used to evaluate relapse. Preliminary analysis of clinician-rated assessments suggests that patients receiving combined therapy were clinically improved at long-term follow-up in comparable percentages to previously published data. Results and clinical implications for combined alprazolam and cognitive-behavioral therapy will be discussed at the conference.